

# Jan Vermorken

Head of Supervisory Board

Medical sciences

PCI BIOTECH

Norway

## Biography

Professor Jan Vermorken served on the medical staff of oncology, at the University Hospital Vrije Universiteit in Amsterdam, The Netherlands, and is Emeritus Professor of Oncology at the University of Antwerp | Oncology at the Antwerp University Hospital in Edegem, Belgium, where he still works as a consultant. His main field of interest is in gynecological and head & neck oncology. In addition, he coordinated large clinical trials in breast and colon cancer, including the

OncoVAX®'s Phase III trial. His main research areas concern early clinical and pharmacological studies with new drugs, studies on the interaction of chemotherapy and radiation therapy, HPV in various and past head of the Department of Medical malignancies and immunological approaches. Dr. Vermorken is a member of the European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group (GCG) and the EORTC Head and Neck Cancer Group (HNCG). He chaired the EORTC-GCG from 1983 to 1989 and the EORTC-HNCG from 2006 to 2009. He is still an active member with both groups. He is an officer for ESMO, was a member of the ESMO executive committee during the time that he chaired the ESMO National Representative Committee (1991 – 1996) and the ESMO Education Committee (1996 – 2002) and is a prominent member of the ESMO faculty. He

is also a member of the International Gynecological Cancer Society (IGCS), was founding chair of the Gynecological Cancer Intergroup (GCIIG) and was Chairman of the Belgian Association of Cancer Research (BACR) from 2003 to 2011, now still being part of its board. Dr. Vermorken is a member of six editorial boards of international journals, reviewer of 13 cancer journals and author or co-author of more than 500 publications in international journals. Dr. Vermorken has been Editor-in-Chief of Annals of Oncology from January 2009 until January 2014. In 2013 he received the title of Commander in the Order of Leopold for his contributions to oncology.